Hospital
Ascension Sacred Heart Gulf
Ascension Sacred Heart Gulf was paid $2.50M by Medicaid between Jan 2018 and Dec 2024, across 59 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoASCENSION SACRED HEART GULF
PORT ST JOE, FL 32456
PORT ST JOE, FL 32456
33aNPI1083941678assigned 11/03/2009
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$2.50M
24GClaims49,179
24DCodes billed59
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,741 | $57K | |
| 2019 | 8,753 | $186K | |
| 2020 | 7,772 | $259K | |
| 2021 | 12,412 | $658K | |
| 2022 | 12,341 | $829K | |
| 2023 | 3,896 | $328K | |
| 2024incomplete | 1,264 | $185K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 6,487 | 5,903 | $783K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 3,855 | 3,356 | $422K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 14% | 2,415 | 695 | $340K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 8.9% | 1,791 | 494 | $224K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 1,416 | 1,212 | $123K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.2% | 1,604 | 484 | $80K |
| 36415 | Collection of venous blood by venipuncture | 2.5% | 2,393 | 2,038 | $63K |
| 80053 | Comprehensive metabolic panel | 2.0% | 4,123 | 3,502 | $50K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 1,492 | 1,440 | $48K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 443 | 409 | $34K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.3% | 1,416 | 1,349 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 1,556 | 1,306 | $31K |
47 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 163 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,318 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 533 | $19K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,124 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 79 | $18K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 137 | $17K |
| 81003 | <1% | 978 | $15K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 205 | $14K |
| 81001 | <1% | 906 | $13K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 563 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,292 | $11K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 323 | $11K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 61 | $9K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 622 | $7K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 150 | $6K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 22 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 763 | $5K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 36 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 375 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 764 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 347 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 117 | $3K |
| 84703 | <1% | 691 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 110 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 767 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 574 | $2K |
| 87634 | <1% | 258 | $2K | |
| 80061 | Lipid panel | <1% | 878 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 414 | $2K |
| 85610 | <1% | 185 | $2K | |
| 84484 | <1% | 380 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 723 | $1K |
| 83690 | <1% | 392 | $815.67 | |
| 85027 | <1% | 124 | $568.15 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 216 | $502.65 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 43 | $465.74 |
| 82607 | <1% | 82 | $385.77 | |
| 84439 | <1% | 15 | $307.69 | |
| 87077 | <1% | 111 | $280.13 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 81 | $278.28 |
| A9270 | Non-covered item or service | <1% | 100 | $259.43 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12 | $220.38 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $8.06 |
| 83735 | <1% | 57 | $7.38 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 13 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 39 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORNEJO, COBA (COO)
| Provider | Location | Paid |
|---|---|---|
| Sacred Heart Health System, INC. | Pensacola, FL | $38.49M |
| Ascension Sacred Heart Emerald Coast | Miramar Beach, FL | $11.93M |
| ST Vincents Health System INC | St. Johns, FL | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.